Argenx SE was founded in 2008 and has its headquarters in Ghent, Belgium. It also has offices in the Netherlands, Japan, and the US. Argenx SE has a market capitalization of about $40 billion as of May 9, 2023, reflecting its strong growth potential and value creation for its shareholders

Argenx SE is committed to improving the lives of people suffering from severe autoimmune diseases and cancer by developing innovative antibody-based therapies. Argenx SE has a diverse and balanced pipeline of clinical and preclinical candidates, targeting novel and validated disease pathways. Some of its lead products include efgartigimod, cusatuzumab and ARGX-11.

The company has a robust pipeline of first-in-class antibodies in both early and late clinical stages of development, targeting various indications such as myasthenia gravis, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and acute myeloid leukemia. The company also has several partnered programs with leading pharmaceutical companies such as AbbVie, Janssen, and Zai Lab.

Argenx SE has received several awards and recognitions for its scientific excellence and business achievements. For example, in 2022, Argenx SE won the Scrip Award for Best Company in Europe, the Fierce Biotech Breakthrough Drug Award for efgartigimod, and the Belgian Biotech Award for Best Biotech Company. Argenx SE also ranked among the top 10 biotech companies in Europe by Labiotech. EU.

Foundation: 2008

Headquarters: Ghent, Belgium

Website: https://www.argenx.com/

UCB was founded in 1928 as a chemical company and has since evolved into a leader in the fields of neurology and immunology. UCB's headquarter is in Brussels, Belgium, and it has operations in more than 40 countries. UCB's market cap is about 16 billion euros as of May 2023.

UCB is committed to creating value for patients, society and shareholders through innovation, collaboration and excellence. UCB has received many awards and recognitions for its achievements in research and development, corporate responsibility and diversity. Some of the recent awards include the European Mediscience Award for Best Technology in 2022, the Corporate Knights Global 100 Most Sustainable Corporations in 2021 and the Catalyst Award for Advancing Women in Business in 2020.

UCB is also involved in many projects and initiatives that aim to improve the lives of people living with severe diseases. For example, UCB is a partner of the Innovative Medicines Initiative (IMI), a public-private partnership that supports the development of new medicines and therapies. UCB is also a member of the Access Accelerated initiative, a global partnership that works to improve access to non-communicable disease prevention, diagnosis and treatment in low- and middle-income countries.

Foundation: 1928
Headquarters: Brussels, Belgium
Website: https://www.ucb.com/

Galapagos NV was founded in 1999 as a joint venture between Crucell and Tibotec. Its headquarters are located in Mechelen, Belgium, and it has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. As of December 31, 2022, Galapagos NV had a market capitalization of €5.8 billion.

Galapagos NV is focused on discovering, developing and commercializing innovative medicines for diseases with high unmet needs. It has a portfolio of programs ranging from discovery to Phase 4 in immunology, oncology and other indications. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Galapagos NV has received several awards for its achievements in the field of biotechnology. In 2019, it won the Scrip Award for Best Company in the EMEA Region. In 2020, it received the European Mediscience Award for Best Technology. In 2021, it was named one of the World's Most Innovative Companies by Fast Company.

Galapagos NV is also committed to advancing the science of cell therapy through its acquisitions of CellPoint and AboundBio in 2022. CellPoint is a leader in allogeneic CAR-T cell therapy for solid tumors. AboundBio is a pioneer in antibody-based gene delivery for rare diseases. These acquisitions will enable Galapagos NV to access next-generation cell therapies that have the potential to transform patients' lives.

Foundation: 1999

Headquarters: Mechelen, Belgium

Website: https://www.glpg.com/

Mithra was founded in 1999 by François Fornieri, a pharmacist and entrepreneur who wanted to create new solutions for women's health issues. Mithra is headquartered in Liège, Wallonia, and has a market cap of about 500 million euros as of May 2023.

Mithra has two complementary pipelines focused on women's health: an innovative Estetrol-based platform and a portfolio of Complex Therapeutics. Estetrol (E4) is a unique estrogen produced by the human fetus during pregnancy that has its own mode of action and benefits for contraception and menopause. Mithra has developed several products based on E4, such as Estelle, a combined oral contraceptive pill; Donesta, a hormone therapy for menopausal symptoms; and PeriNesta, a hormone therapy for perimenopausal symptoms.

Mithra also has a portfolio of Complex Therapeutics, which are generic or hybrid versions of existing drugs that have improved features or formulations. These include Myring, a vaginal ring for contraception; Tibelia, a hormone therapy for menopause; and Zoreline, an implant for prostate cancer and endometriosis.

Mithra has received several awards and recognitions for its innovation and performance, such as the Belgian Biotech Award in 2019, the Trends Gazelles Award in 2020 and 2021, and the Euronext Tech Leader Award in 2021. Mithra also has a strong commitment to environmental, social, and governance (ESG) principles, as reflected in its annual report and ESG strategy.

Foundation: 1999
Headquarters: Wallonia, Belgium
Website: https://www.mithra.com/en/

Oxurion was founded in 1996 as ThromboGenics, a spin-off from the University of Leuven in Belgium. The company changed its name to Oxurion in 2018 to reflect its focus on ophthalmology. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.

Oxurion has a market cap of about 200 million euros as of May 2023. The company has a strong cash position of 70 million euros as of December 2022, which allows it to fund its clinical development programs and pursue strategic partnerships.

Oxurion's main product candidate is THR-149, a potent plasma kallikrein inhibitor for the treatment of DME. DME is a complication of diabetes that causes swelling and damage to the retina, leading to vision loss. Up to 50% of DME patients do not respond well to anti-VEGF therapies, the current standard of care. THR-149 has shown promising results in a phase 2 trial, improving vision and reducing retinal thickness in DME patients who are suboptimal responders to anti-VEGF therapy.

Oxurion has received several awards and recognitions for its scientific excellence and innovation. In 2020, Oxurion won the Belgian Biotech Award for Best Biotech Company. In 2021, Oxurion was selected as one of the Fierce 15 Biotech Companies by Fierce Biotech, a leading industry publication. In 2022, Oxurion was named as one of the Top 10 Ophthalmology Companies by Pharma Tech Outlook, a magazine that showcases the latest trends and innovations in the pharmaceutical industry.

Foundation: 1996

Headquarters: Leuven, Belgium

Website: https://oxurion.com/

Biocartis Group NV is an innovative molecular diagnostics company that aims to revolutionize molecular testing with its unique proprietary IdyllaTM platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis has a market cap of about 1.2 billion euros as of May 2023.

Biocartis focuses on oncology and infectious disease testing, offering rapid, in-house biomarker testing for fast treatment decisions. The company has developed a portfolio of tests for various cancers, such as lung, colorectal, melanoma, and breast cancer. Biocartis also collaborates with pharmaceutical and diagnostic companies to develop companion diagnostics and novel biomarkers.

Biocartis has the vision to make personalized medicine accessible and actionable for everyone. The company believes that molecular diagnostics can improve clinical practice and patient outcomes by providing timely and accurate information for the diagnosis, prognosis, therapy selection, and monitoring. Biocartis is committed to advancing the future of personalized medicine with its innovative solutions.

The IdyllaTM platform is a revolutionary, fully automated system that makes molecular testing convenient and affordable. It can perform complex molecular analyses from a single cartridge using a small sample of tissue or blood. The platform delivers results in only 3 hours, compared to days or weeks for conventional methods. The IdyllaTM platform is suitable for any lab setting and does not require specialized personnel or infrastructure.

Foundation: 2007
Headquarters: Mechelen, Belgium
Website: https://www.biocartis.com/en

MDxHealth SA is a leading molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and personalized treatment. The company was founded in 2003 as OncoMethylome Sciences and changed its name to MDxHealth in 2010. The company is headquartered in Herstal, Belgium, with a US subsidiary in Irvine, California.

MDxHealth has a market capitalization of about $0.5B as of April 11, 2023, according to Yahoo Finance. The company is listed on the Euronext Brussels exchange under the ticker symbol MDXH.

The company's vision is to revolutionize the management of urologic cancers by providing accurate and actionable information to patients and physicians. The company's main products are SelectMDx and ConfirmMDx, two non-invasive urine tests that help detect and monitor prostate cancer.

SelectMDx is a liquid biopsy test that measures the expression of two biomarkers associated with aggressive prostate cancer. The test helps identify patients at high risk of having clinically significant prostate cancer who may benefit from a prostate biopsy. ConfirmMDx is a tissue-based test that analyzes the methylation status of three genes involved in prostate cancer. The test helps rule out false-negative biopsy results and avoid unnecessary repeat biopsies.

MDxHealth also offers other tests for bladder, kidney, and colorectal cancers, as well as services for pharmaceutical and biotech companies, such as biomarker discovery, assay development, and clinical trial support.

Foundation: 2003

Headquarters: Herstal, Belgium

Website: https://mdxhealth.com/

Bone Therapeutics SA is a Belgium-based company that develops cell therapy products for treating and regenerating bone tissue and bone reconstruction applications. The company was founded in 2006 and has its headquarters in Mont-Saint-Guibert, Belgium. As of April 11, 2023, the company had a market cap of 17.98 million euros. Recently, Bone Therapeutics SA has changed its name to BioSenic following the acquisition of a majority participation of Medsenic valued at EUR 40 million.

The company's vision is to become a leader in cell therapy for bone diseases and to address unmet medical needs in orthopedics and other diseases. The company's leading product candidates are ALLOB, an allogeneic osteoblastic cell therapy product derived from bone marrow mesenchymal stem cells, and JTA-004, a protein solution for the treatment of osteoarthritis.

The company is currently conducting several clinical trials with its product candidates in various indications, such as difficult fractures, osteonecrosis, spinal fusion, knee osteoarthritis, and maxillo-facial reconstruction. The company also recently entered into exclusive reverse merger discussions with Medsenic, a privately held biopharmaceutical company specializing in developing arsenic salts for inflammatory conditions. The objective of the potential transaction is to create a fully integrated biopharmaceutical company with a diverse therapeutic portfolio targeting a broad array of inflammatory and orthopedic indications.

Bone Therapeutics SA is committed to advancing the field of cell therapy for bone diseases and to bringing innovative solutions to patients in need.

Foundation: 2006
Headquarters: Mont-Saint-Guibert, Belgium
Website: https://www.biosenic.com/

Sequana Medical NV is a Belgian company founded in 2006 that develops innovative treatments for fluid overload using its proprietary alfa pump® and DSR® (Direct Sodium Removal) technologies. Sequana Medical NV has its headquarters in Ghent, Belgium, and has offices in Zurich, Switzerland, and Düsseldorf, Germany. As of May 9, 2023, Sequana Medical NV has a market capitalization of EUR 101.4 million based on a share price of EUR 3.36.

Sequana Medical NV has developed two innovative technologies: the alfa pump® system and the DSR® (Direct Sodium Removal) therapy. The alfa pump® system is a fully implantable device that automatically pumps excess fluid from the abdomen into the bladder, where it is naturally eliminated through urination. The alfa pump® system has been approved in Europe since 2011 and has been used by more than 900 patients. The alfa pump® system is currently under clinical investigation in the US and Canada (POSEIDON Study) for patients with refractory or recurrent ascites due to cirrhosis.

Sequana Medical NV has the vision to become a leader in innovative treatment solutions for fluid overload. The company is currently conducting clinical trials for its alfa pump® system in the US and Canada for patients with refractory or recurrent ascites due to cirrhosis. The company is also developing its DSR® therapy for patients with heart failure and diuretic-resistant fluid overload.

Foundation: 2006

Headquarters: Ghent, Belgium

Website: https://www.sequanamedical.com/

Ablynx NV is a biotechnology company that was founded in 2001 as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). The company is based in Ghent, Belgium, and has about 450 employees. Since then, it has grown to become a leader in nanobody technology, with more than 500 pending and granted patents and a pipeline of over 45 programs in different stages of development.

Ablynx's main focus is on the discovery and development of nanobodies, which are proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are derived from the heavy-chain-only antibodies found in llamas and other camelids and are about a tenth the size of conventional antibodies. This makes them more stable, versatile, and easy to produce than conventional antibodies .

Ablynx NV is also collaborating with several pharmaceutical companies, such as Sanofi, Merck & Co., Boehringer Ingelheim, and Novartis, to develop nanobody products for various indications, such as immuno-oncology, inflammation, hematology, and neuroscience.

Ablynx's vision is to become a leading biopharmaceutical company that leverages nanobody technology to create innovative and life-changing medicines for patients. The company's mission is to deliver on the promise of nanobodies by applying its scientific expertise, creativity, and passion to address unmet medical needs. Ablynx's values are excellence, innovation, teamwork, respect, and integrity.

Foundation: 2001
Headquarters: Ghent, Belgium
Website: http://www.ablynx.com